Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Actuate Therapeutics , Inc., a biopharmaceutical company with a market capitalization of $172 million, announced today that it will hold its first Annual Meeting of Stockholders virtually on May 22, ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

President Donald Trump signed executive orders imposing tariffs on almost all imports from Canada, Mexico and China. Tariffs ...